Abbott's Vicodin CR draws FDA "complete response"
This article was originally published in Scrip
The US FDAhas issued a "complete response" letter to Abbottfor a controlled-release formulation of the pain killer Vicodin (hydrocodone plus acetaminophen). The company will discuss the letter with the agency and provide an update "when appropriate". If approved, Vicodin CR would be the first extended-release formulation of hydrocodone with acetaminophen, providing pain relief for more than 12 hours. Currently available short-acting formulations of hydrocodone with acetaminophen have to be taken every four to six hours. Although Abbott did not provide specifics about the complete response letter, the agency may have concerns about the new formulation's abuse potential and could require a risk evaluation and mitigation strategy (REMS). Hydrocodone is the most frequently prescribed opiate in the US and diversion and abuse have escalated in recent years.
You may also be interested in...
Operation Warp Speed will hold back initial shipments to ensure two-dose regimens can be completed; 15 December is ‘chalk’ target date for emergency authorization of Pfizer vaccine, OWS’ Gustave Perna says, calling it only a projection that does not impinge on FDA authority. Sending only half shipments also eases burden on cold shortage capacity at state and local level, he says.
COVID-19 Vaccines: ACIP’s Allocation Proposal Prioritizes Long-Term Care Residents, Essential Workers
First group to receive vaccine would comprise health care personnel and residents of long-term care facilities; next in line are non-health care essential workers, who would take priority over adults with high-risk medical conditions and those ages 65 years and older, according to the CDC advisory committee’s proposed allocation framework.
Although US FDA wants sponsors to maintain blinded Phase III follow-up as long as possible after emergency use authorization or licensure, vaccine researcher Larry Corey says it will become ‘untenable’ to keep individuals in placebo arm once they qualify for vaccine access under the allocation framework.